- GlobeNewswire•5 days agoPreliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
PORTLAND, Ore., Sept. 26, 2016-- Entia Biosciences, Inc. Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected preliminary results in the Company’ s chronic ...
- Accesswire•last yearEntia Biosciences, Inc. Names Chief Executive Officer to Manage Growth of Consumer Health Products and To Launch New Medical Food Brands
New Business Strategy to Capitalize on Unique, Innovative and Proprietary Entia Products SHERWOOD, OR / ACCESSWIRE / August 13, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), today announced that Carl J. ...
- Accesswire•last year
PORTLAND, OR / ACCESSWIRE / July 9, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company's GROH(R) Professional brand ...
Entia Biosciences, Inc (ERGO)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.64|
|Avg Vol (3m)||6,863|
|Dividend & Yield||N/A (N/A)|